Post by tomsylver on Oct 24, 2017 6:51:38 GMT
WALTHAM, Mass., Oct. 23, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences. The two conferences are:
The Credit Suisse 26th Annual Healthcare Conference at The Phoenician in Scottsdale, Arizona on Monday, November 6 and Tuesday, November 7. Lonnie Moulder, CEO of TESARO, and Mary Lynne Hedley, Ph.D., President and COO of TESARO, are scheduled to participate in an analyst-led fireside chat at 10:55 AM MT on Tuesday, November 7, and will also host meetings with investors.
The Evercore ISI BioPharma Catalyst/Deep Dive Conference at the Boston Harbor Hotel in Boston on Wednesday, November 29. Lonnie Moulder, CEO of TESARO, and Mary Lynne Hedley, Ph.D., President and COO of TESARO, are scheduled to participate in an analyst-led fireside chat from 3:50 to 4:35 PM ET on Wednesday, November 29, and will also host meetings with investors.
Live webcasts of the presentations at the Credit Suisse and Evercore ISI conferences will be available by visiting the Investors section of the TESARO website at www.tesarobio.com. Archived replays of these webcasts will be available on the Company’s website for 14 days following the conferences.
About TESARO
TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. For more information, visit www.tesarobio.com, and follow us on Twitter and LinkedIn.
For additional information, please contact:
Jennifer Davis
Vice President, Corporate Communications & Investor Relations
+1.781.325.1116 or jdavis@tesarobio.com
The Credit Suisse 26th Annual Healthcare Conference at The Phoenician in Scottsdale, Arizona on Monday, November 6 and Tuesday, November 7. Lonnie Moulder, CEO of TESARO, and Mary Lynne Hedley, Ph.D., President and COO of TESARO, are scheduled to participate in an analyst-led fireside chat at 10:55 AM MT on Tuesday, November 7, and will also host meetings with investors.
The Evercore ISI BioPharma Catalyst/Deep Dive Conference at the Boston Harbor Hotel in Boston on Wednesday, November 29. Lonnie Moulder, CEO of TESARO, and Mary Lynne Hedley, Ph.D., President and COO of TESARO, are scheduled to participate in an analyst-led fireside chat from 3:50 to 4:35 PM ET on Wednesday, November 29, and will also host meetings with investors.
Live webcasts of the presentations at the Credit Suisse and Evercore ISI conferences will be available by visiting the Investors section of the TESARO website at www.tesarobio.com. Archived replays of these webcasts will be available on the Company’s website for 14 days following the conferences.
About TESARO
TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. For more information, visit www.tesarobio.com, and follow us on Twitter and LinkedIn.
For additional information, please contact:
Jennifer Davis
Vice President, Corporate Communications & Investor Relations
+1.781.325.1116 or jdavis@tesarobio.com